Medical science monitor : international medical journal of experimental and clinical research · 2009
Effect of meglumine antimoniate on the pancreas during treatment of visceral leishmaniasis in children.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shahian Mozhgan, Alborzi Abdolvahab
Аннотация
BACKGROUND: Pentavalent antimonials are among the first-line drugs for treating visceral leishmaniasis (VL). Acute pancreatitis is a rare toxic adverse effect of therapy with antimonial compounds in adults. This study evaluated the effect of maglumine antimoniate on the pancreas in children treated for VL.
MATERIAL/METHODS: A prospective study was conducted on 20 children with VL who were treated with 20 mg/kg/day maglumine antimoniate until one week after defervescence. No patient had immunosuppression caused by HIV infection, renal transplantation, or drugs. Serum levels of amylase and lipase were measured at baseline and after 2, 4, 6, 9, and12 days of therapy.
RESULTS: During therapy, all cases had normal serum levels of amylase except for one. Serum lipase levels rose to abnormal levels in five patients, two of whom had minimally (i.e. <20% above the upper limit of normal) elevated serum lipase levels at pretreatment. All the five cases had normal serum amylase levels. There were no clinical signs or symptoms of pancreatitis in the patients.
CONCLUSIONS: It may be concluded that acute pancreatitis or hyperamylasemia are not potential complications with this therapeutic regime among immunocompetent children with VL and that routine monitoring of these patients for serum amylase and lipase levels is not necessary.
MATERIAL/METHODS: A prospective study was conducted on 20 children with VL who were treated with 20 mg/kg/day maglumine antimoniate until one week after defervescence. No patient had immunosuppression caused by HIV infection, renal transplantation, or drugs. Serum levels of amylase and lipase were measured at baseline and after 2, 4, 6, 9, and12 days of therapy.
RESULTS: During therapy, all cases had normal serum levels of amylase except for one. Serum lipase levels rose to abnormal levels in five patients, two of whom had minimally (i.e. <20% above the upper limit of normal) elevated serum lipase levels at pretreatment. All the five cases had normal serum amylase levels. There were no clinical signs or symptoms of pancreatitis in the patients.
CONCLUSIONS: It may be concluded that acute pancreatitis or hyperamylasemia are not potential complications with this therapeutic regime among immunocompetent children with VL and that routine monitoring of these patients for serum amylase and lipase levels is not necessary.